PDAPS | Prescription Drug Abuse Policy System

Resources

Papers in Peer-Reviewed Publications Citing PDAPS
    2018
  1. 1

    Alexandra, S., Fahad, K., Alina, B., Germaine, C., Christopher, G., & V., D. L. (2018).

    New York Physicians' Perspectives and Knowledge of the State Medical Marijuana Program.

    Cannabis and Cannabinoid Research, 3(1), 74-84. doi: 10.1089/can.2017.0046

  2. 2

    Bennett, A. S., Bell, A., Doe-Simkins, M., Elliott, L., Pouget, E., & Davis, C. (2018).

    From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA.

    Journal of Psychoactive Drugs, 1-7. doi: 10.1080/02791072.2018.1430409

  3. 3

    Buchmueller, T. C., & Carey, C. (2018).

    The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare.

    American Economic Journal: Economic Policy, 10(1), 77-112. doi: doi: 10.1257/pol.20160094

  4. 4

    Freeman, P. R., Hankosky, E. R., Lofwall, M. R., & Talbert, J. C. (2018).

    The changing landscape of naloxone availability in the United States, 2011 – 2017.

    Drug and Alcohol Dependence, 191, 361-364. doi: https://doi.org/10.1016/j.drugalcdep.2018.07.017

  5. 5

    Gertner, A. K., Domino, M. E., & Davis, C. S. (2018).

    Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid.

    Drug Alcohol Depend, 190, 37-41. doi: 10.1016/j.drugalcdep.2018.05.014

  6. 6

    Goldberg, S. A., Dworkis, D. A., Liao, V. T., Eyre, A. J., Albert, J., Fawcett, M. M., . . . Weiner, S. G. (2018).

    Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose.

    Prehospital Emergency Care, 1-7. doi: 10.1080/10903127.2018.1461284

  7. 7

    Huang, L. C. (2018).

    Opioid Overdoses: A Webliography.

    Journal of Consumer Health on the Internet, 22(1), 42-52. doi: 10.1080/15398285.2018.1415597

  8. 8

    McClellan, C., Lambdin, B. H., Ali, M. M., Mutter, R., Davis, C. S., Wheeler, E., . . . Kral, A. H. (2018).

    Opioid-overdose laws association with opioid use and overdose mortality.

    Addictive Behaviors, 86, 90-95. doi: https://doi.org/10.1016/j.addbeh.2018.03.014

  9. 9

    Pauly, N. J., Slavova, S., Delcher, C., Freeman, P. R., & Talbert, J. (2018).

    Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings.

    Drug and Alcohol Dependence, 184, 26-32. doi: https://doi.org/10.1016/j.drugalcdep.2017.12.002

  10. 10

    Xu, J., Davis, C. S., Cruz, M., & Lurie, P. (2018).

    State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies.

    Drug & Alcohol Dependence, 189, 37-41. doi: 10.1016/j.drugalcdep.2018.04.020

  11. 11

    Lambdin, B. H., Zibbell, J., Wheeler, E., & Kral, A. H. (2018).

    Identifying gaps in the implementation of naloxone programs for laypersons in the United States.

    International Journal of Drug Policy, 52, 52-55. doi: https://doi.org/10.1016/j.drugpo.2017.11.017

  12. 12

    W. Ling, V. Nadipelli, N. Ronquest, V. Albright, A. Aldridge, S. Learned, V. Mehra, C. Heidbreder. (2018).

    Remission from chronic opioid use—Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics.

    Concli.

  13. 2017
  14. 13

    Burris, S. (2017).

    Theory and methods in comparative drug and alcohol policy research: Response to a review of the literature.

    International Journal of Drug Policy, 41, 126-131. doi: http://dx.doi.org/10.1016/j.drugpo.2016.11.011

  15. 14

    Compton, W. M., Volkow, N. D., & Lopez, M. F. (2017).

    Medical marijuana laws and cannabis use: Intersections of health and policy.

    JAMA Psychiatry, 74(6), 559-560. doi: 10.1001/jamapsychiatry.2017.0723

  16. 15

    Cushman, P. A., Liebschutz, J. M., Hodgkin, J. G., Shanahan, C. W., White, J. L., Hardesty, I., & Alford, D. P. (2017).

    What do providers want to know about opioid prescribing? A qualitative analysis of their questions.

    Substance Abuse, 38(2), 222-229. doi: 10.1080/08897077.2017.1296525

  17. 16

    Davis, C., & Carr, D. (2017).

    State legal innovations to encourage naloxone dispensing.

    Journal of the American Pharmacists Association, 57(2, Supplement), S180-S184. doi: https://doi.org/10.1016/j.japh.2016.11.007

  18. 17

    Klieger, S. B., Gutman, A., Allen, L., Pacula, R. L., Ibrahim, J. K., & Burris, S. (2017).

    Mapping medical marijuana: State laws regulating patients, product safety, supply chains and dispensaries, 2017.

    Addiction, n/a-n/a. doi: 10.1111/add.13910

  19. 18

    Lapham, G. T., Lee, A. K., Caldeiro, R. M., McCarty, D., Browne, K. C., Walker, D. D., . . . Bradley, K. A. (2017).

    Frequency of Cannabis Use Among Primary Care Patients in Washington State.

    The Journal of the American Board of Family Medicine, 30(6), 795-805. doi: 10.3122/jabfm.2017.06.170062

  20. 19

    Pardo, B. (2017).

    Do more robust prescription drug monitoring programs reduce prescription opioid overdose?

    Addiction, 112(10), 1773-1783. doi: 10.1111/add.13741

  21. 20

    Volkow, N. D., Compton, W. M., & Wargo, E. M. (2017).

    The risks of marijuana use during pregnancy.

    JAMA, 317(2), 129-130. doi: 10.1001/jama.2016.18612

  22. 2016
  23. 21

    Burris, S., Hitchcock, L., Ibrahim, J. K., Penn, M., & Ramanathan, T. (2016).

    Policy Surveillance: a Vital Public Health Practice Comes of Age.

    Journal of Health Politics, Policy & Law, 41(6), 1151-1167. doi: 10.1215/03616878-3665931

  24. 22

    Davis, C. S., Burris, S., Beletsky, L., & Binswanger, I. (2016).

    Co-prescribing naloxone does not increase liability risk.

    Substance Abuse, 37(4), 498-500. doi: 10.1080/08897077.2016.1238431

  25. 23

    Kitch, B. B., & Portela, R. C. (2016).

    Effective Use of Naloxone by Law Enforcement in Response to Multiple Opioid Overdoses.

    Prehospital Emergency Care, 20(2), 226-229. doi: 10.3109/10903127.2015.1076097

  26. 24

    Patrick, S. W., Fry, C. E., Jones, T. F., & Buntin, M. B. (2016).

    Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates.

    Health Affairs, 35, 1045-1051. doi: 10.1377/hlthaff.2015.1496

  27. 2015
  28. 25

    Green, T. C., Bowman, S., Davis, C., Los, C., McHugh, K., & Friedmann, P. D. (2015).

    Discrepancies in Addressing Overdose Prevention through Prescription Monitoring Programs.

    Drug & Alcohol Dependence. doi: 10.1016/j.drugalcdep.2015.05.009

  29. 26

    Rutkow, L., Chang, H., Daubresse, M., Webster, D. W., Stuart, E. A., & Alexander, G. (2015).

    Effect of Florida’s prescription drug monitoring program and pill mill laws on opioid prescribing and use.

    JAMA Internal Medicine, 175(10), 1642-1649. doi: 10.1001/jamainternmed.2015.3931

  30. 27

    Rutkow, L., Turner, L., Lucas, E., Hwang, C., & Alexander, G. C. (2015).

    Most Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To Access.

    Health Affairs, 34(3), 484-492. doi: 10.1377/hlthaff.2014.1085

Other Prescription Drug Abuse Policy Datasets
  1. 1

    Sonderegger Research Center, University of Wisconsin-Madison School of Pharmacy. State Laws and Other Regulatory Policies Related to Pain Care Map.

    Policy Surveillance Program: A LawAtlas Project. Valid through December 31, 2017. Available at: http://lawatlas.org/datasets/state-laws-and-other-regulatory-policies-related-to-pain-care-final.

  2. 2

    Heins, S.E. Morphine Equivalent Daily Dose (MEDD) Policies Map.

    Policy Surveillance Program: A LawAtlas Project. Valid through June 1, 2017. Available at: http://lawatlas.org/datasets/morphine-equivalent-daily-dose-medd-policies.